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Abstract
Background: Worldwide caesarean section (CS) delivery is the most common major operation. Approximately 25%
of pregnant women undergo a CS in the UK for delivery of their babies. Sepsis and post-natal infection constitute
significant maternal mortality and morbidity. Infection following a CS has a number of primary sources including
endometritis occurring in 7–17% of women. Sepsis reduction and reduction in antibiotic use have been identified
as a national and international priority. The overarching aim of this research is to reduce infectious morbidity from
caesarean sections.
Methods: This is a parallel group feasibility randomised controlled trial comparing vaginal cleansing using
chlorhexidine gluconate versus no cleansing (standard practice) at CS to reduce infection. Women will be recruited
from four National Health Service maternity units. Two hundred fifty women (125 in each arm) undergoing elective
or emergency CS, who are aged 16 years and above, and at least 34 weeks pregnant will be randomised. Allocation
to treatment will be on a 1:1 ratio. The study includes a qualitative aspect to develop women centred outcomes of
wellbeing after delivery.
Discussion: The success of the feasibility study will be assessed by criteria related to the feasibility measurements
to ascertain if a larger study is feasible in its current format, needs modification or is unfeasible, and includes
recruitment, adherence, follow-up and withdrawal measures.
Trial registration: The PREPS trial has been registered with ISRCTN (ISRCTN 33435996).
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Background
Justification for participant population
Worldwide caesarean section (CS) delivery is the most
common major operation. Approximately 25% of preg-
nant women undergo a CS in the UK for delivery of
their babies. This equates to approximately 171,000 cae-
sarean sections per year in England alone.
Sepsis and post-natal infection constitute significant ma-
ternal mortality and morbidity, as well as having significant
impact on post-natal recovery and maternal wellbeing. In-
fection following a CS has numerous primary sources in-
cluding endometritis, occurring in 7–17% of women; this
equates to approximately 27,000 cases of infection per year
in England only. Risk factors for endometritis following CS
include in labour caesarean section and ruptured mem-
branes with or without vaginal colonisation with group B
streptococcus. Sepsis reduction and reduction in antibiotic
use have been identified as national and international prior-
ities, improving maternal health and neonatal wellbeing
through the facilitation of ongoing breast feeding.
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Justification for intervention
Prophylactic antibiotics at the time of surgery have been
demonstrated to be beneficial in a number of large ran-
domised controlled trials (RCT) and continue to reduce
infection rates [1]. Current practice of skin preparation
[2] is guided by a recent RCT demonstrating the super-
iority of a chlorhexidine over an iodine-based solution
[3]. In addition to skin preparation with an antiseptic so-
lution, cleansing inside the vagina with povidone iodine
has been evaluated [4]. A Cochrane review of seven trials
randomising 2816 women (2635 analysed) estimated the
effects of vaginal cleansing (all with povidone-iodine) on
post-caesarean infectious morbidity [4]. Vaginal prepar-
ation immediately before caesarean delivery significantly
reduced the incidence of post-caesarean endometritis
from 8.3% in control groups to 4.3% in vaginal cleansing
groups (average risk ratio (RR) 0.45, 95% confidence
interval (CI) 0.25 to 0.81, seven trials, 2635 women).
The risk reduction was particularly strong for women
who were already in labour at the time of the caesarean
delivery (7.4% in the vaginal cleansing group versus 13.
0% in the control group; RR 0.56, 95% CI 0.34 to 0.95,
three trials, 523 women) and for women with ruptured
membranes (4.3% in the vaginal cleansing group versus
17.9% in the control group; RR 0.24, 95% CI 0.10 to 0.
55, three trials, 272 women [4]). The above would ap-
pear an effective and important strategy to reduce mor-
bidity at CS, yet this has not been adopted within
obstetric practice internationally and does not feature
within the NICE Intrapartum guideline [5]. This is due
to concerns with exposure of the fetus to iodine-based
substances, concerns with vaginal staining and allergy to
iodine. Iodine is a recognised antibacterial agent, but in-
activity by the presence of blood [6] limits its use. Thus,
there are a number of reasons to believe that vaginal
cleansing with chlorhexidine would be an appropriate al-
ternative to povidone iodine. Some studies show greater
reduction in skin flora after application of chlorhexidine
(0.5 and 4%) [6] compared with povidone-iodine agents.
Also, chlorhexidine may have a greater residual activity
after application than other preparations and, unlike
povidone iodine, it is not inactivated by the presence of
blood. Solutions that contain lower concentrations, such
as the commonly used chlorhexidine gluconate and acet-
ate (0.05%), are usually well tolerated and may be used
for vaginal preparation [6]. With this preparation, there
are no reported cases of allergy. There is one small ran-
domised controlled trial comparing povidone iodine with
chlorohexidine gluconate for vaginal cleansing at CS.
This suggested that chlorohexidine may be superior, and
further research was needed [7].
A Cochrane review of cleansing the vagina in normal
vaginal delivery with chlorhexidine showed no evidence
of an effect on maternal or neonatal infections with low
to moderate confidence, although further large scale
trials to detect small but clinically important differ-
ences were needed. Importantly, no safety concerns
for the mother or baby have been identified within
these studies [8].
Methods
Aims
The overarching aim of this research is to reduce infec-
tious morbidity from caesarean sections. Specific objec-
tives for this feasibility study include:
 To determine appropriate recruitment and
randomisation processes
 To assess if women can remain blinded to the trial
intervention
 To determine the sample size required for a
definitive trial
 To inform if the intervention can be conducted in a
multi-centre RCT
 To develop women focused outcome measures and
method of data collection
 To assess data collection of clinical outcomes up to
6 weeks
 To assess withdrawals
Qualitative study design
A qualitative study will inform the outcomes that will be
collected on women in the feasibility RCT. Two focus
groups will be performed at the lead site (Birmingham
Women’s and Children’s Hospital BWCH) of approxi-
mately 7 to 10 women in each group who have undergone
a CS and would like to contribute to the development of
women-centred outcomes.
Women will be recruited via adverts placed on BWCH
notice boards and on the post-natal wards, through so-
cial media platforms; community midwives will be asked
to identify women, as well as hospital midwives if
women re-attend and through patient engagement ser-
vices at BWCH. We will ask women who have had a CS
within the previous 6 months to contribute to focus
groups on important women-centred outcomes for re-
search into infection and complications following a CS.
The focus groups will be performed prior to com-
mencement of recruitment to the feasibility RCT and
thus used to decide on outcomes for inclusion in the
feasibility trial that the women feel are important for
post-natal quality of life and recovery. All women will
have demographic data collected. The focus groups will
be recorded and transcribed anonymously. The data will
be analysed thematically and managed using the Frame-
work Method [9]. An experienced qualitative researcher
will run the focus groups, with the support of a research
associate and the clinical research fellow.
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From informal discussions with women who have
undergone CS, the outcomes are likely to be composed
of the following themes:
 Length of midwife follow-up
 Prolonged use of analgesics
 Ability to care for self
 Time to leaving house with family/independently
 Ability to care for a baby
Feasibility study design
Blinded to women and personnel performing outcome
collection, parallel group, feasibility RCT compared vagi-
nal cleansing using chlorhexidine gluconate or acetate
versus no cleansing (standard practice) at CS to reduce
infection. Allocation to treatment will be on a 1:1 ratio.
A feasibility randomised controlled trial design is being
undertaken to test the consent and randomisation pro-
cesses for women requiring a CS, and the follow-up pro-
cesses up until the immediate post-natal period, to ensure
we can overcome the challenges this poses.
Trial setting
The trial will be undertaken in maternity hospitals:
Birmingham Women’s and Children’s Hospital, Birming-
ham Heartlands Hospital, Shrewsbury and Telford
Hospital (West Midlands) and Sunderland Royal Hospital,
to ensure the trial can be extrapolated to a larger multi-
centre trial.
Identification of participants
Given recruitment, consent and randomisation processes
will differ for emergency and elective CS due to differ-
ences in planning for surgery; the processes for each
type of surgery will be detailed separately. All women
booking at any of the hospitals over the study period
and who are greater than 34 weeks pregnant while re-
cruitment is running will be posted a patient informa-
tion leaflet. This is to ensure that all women are aware
of the study before delivery of their baby/babies. This
will be accompanied with patient information leaflets
and study information being available in antenatal clinics
and triage waiting rooms. Study posters will also be dis-
played in prominent positions through the hospitals.
Eligibility criteria and co-enrolment
Women will be included in the trial if they are as
follows:
 Greater than or equal to 34 weeks pregnant
 Having a CS
 Able to give informed written consent
 Able to receive a telephone interview at 14 and
30 days post-natal
 Aged 16 years or over
Women will be excluded from the trial if they:
 Have a known allergy to chlorhexidine gluconate or
any of its ingredients
 Are receiving prophylactic intravenous antibiotics
for group B streptococcus (GBS) colonisation
 Are receiving intravenous antibiotics for suspected
infection (standard CS intravenous prophylaxis is
not an exclusion criteria)
 Are currently enrolled in an RCT for an intervention
intended to reduce post-operative surgical site infection
All women already enrolled in an interventional study
are permitted to be co-enrolled into PREPS, as long as
the intervention is not intended to reduce infection.
After consent and randomisation to PREPS, women will
not be permitted to enter a further interventional study
if the study is evaluating the prevention of infection. Co-
enrolment in all observational studies is permitted.
Randomisation
After the woman’s eligibility has been confirmed and in-
formed consent has been received, the woman can be
randomised into the trial (Fig. 1). Randomisation can be
performed by all members of the research team and clin-
ical team and is most likely to be performed by dedi-
cated research midwives.
Randomisation will be provided by a secure automated
telephone randomisation system available 24 h a day/
7 days a week provided by the University of Aberdeen.
The telephone randomisation service will comply with
research and governance standards.
The randomised allocation will be documented in the
main hospital records on the anaesthetic chart, on a
dedicated sticker within the patient notes and on the
relevant case report forms. The allocation will not be
disclosed to the woman or recorded in the post-natal
hand-held notes.
Women will be randomised at the level of the individ-
ual in a 1:1 ratio to either chlorohexidine gluconate or
acetate 0.05% vaginal cleansing or standard treatment of
no vaginal cleansing. A minimisation algorithm will be
used to ensure balance in the treatment allocation over
the following variables:
 Randomising centre
 In labour and not in labour CS
A ‘random element’ will be included in the minimisa-
tion algorithm so that each patient has a probability (un-
specified here) of being randomised to the opposite
treatment that they would have otherwise received.
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Blinding
The trial cannot be blinded to the operator or the
clinical care team in theatre providing care to the
women due to the nature of the intervention. Ran-
domisation will be performed by a wide range of staff
from theatre runners to consultants. Randomisation
may be performed by dedicated research midwives
who will also collect outcome data from the notes,
but there will be no recording of the allocation in the
post-natal notes.
Attempts will be made to blind the women as the
intervention will be applied at the time of the catheter
insertion, and the woman should not be aware of the ap-
plication due to anaesthesia.
All data collection from the maternal notes will be
blinded since there will only be recording of whether the
intervention was applied on the theatre operation note
and anaesthetic/operation chart, which are not held in
the maternal post-natal notes. As a part of the monitor-
ing process, 10% of medical records will be independ-
ently monitored and data collection will be verified by
the trial sponsor on-site.
The research midwife conducting the telephone
follow-up interviews will be blinded to the treatment
group so that there will be no bias in the collection of
outcomes. The research midwife will not have an access
to the medical records or any data collection forms at
the time of telephone interviews.
At the end of the 14-day interview, the midwife will
ask the woman whether she feels she received the inter-
vention or not to assess whether blinding of the woman
is an achievable aim.
Fig. 1 Trial participant flow
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Intervention
Chlorohexidine gluconate 0.05% or chlorohexidine acet-
ate 0.05% will be used to perform vaginal cleansing. The
active ingredient is chlorhexidine 0.05%. This is indi-
cated within the British National Formulary for swab-
bing in obstetrics.
Fifty millilitres of antiseptic (chlorohexidine gluconate
0.05% or chlorohexidine acetate 0.05%) will be emptied
into a sterile pot. A single swab/sponge mounted on a
sponge holder soaked in the antiseptic will be used to
clean the vagina prior to CS at the time of urinary cath-
eter insertion, for guidance, we suggest the vaginal
cleansing should take 30 s. Following the CS procedure,
the vagina will be cleaned of excess blood as is standard
practice with a dry swab. The application of the inter-
vention is quick and familiar to the doctors performing
the surgery due to their experience in gynaecological
surgery where it is routine practice. All theatres’ stand-
ard operating procedures regarding swabs and instru-
ment counts should be adhered to, to ensure patient
safety. At all sites, staff will be asked to record if they
have performed vaginal cleansing, and if performed,
which antiseptic was used, on the CS operation note
within the hospital notes.
Outcomes
All feasibility outcomes will be assessed overall and by
centre. Recruitment will take place for a minimum of
12 weeks and a maximum of 20 weeks, across the four
maternity sites.
Stop-go criteria
The decision to continue to a full trial will be decided by
pre-defined stop-go criteria based on the following
outcomes:
 The proportion of women randomised into the trial
of the 250 recruitment target
 The proportion of women who received their
allocated intervention out of all those randomised
 The proportion of women remaining in the trial
(i.e. not withdrawn) who successfully complete the
planned follow-up process for both the 14- and
30-day telephone interview
 Withdrawal from the study
Other feasibility outcomes
 The proportion of eligible women approached to
take part
 The proportion of women randomised who have an
elective/emergency CS
 The proportion of women who are randomised into
the PREPS trial with verbal consent from the
number of women whom have an emergency CS
 The proportion of women randomised who can
successfully identify what treatment they received
(i.e. vaginal cleansing or no vaginal cleansing)
 The proportion of complete data for each of the
clinical and woman reported outcomes of women
randomised
 Time taken to perform the telephone interviews
 Reasons for withdrawal
Clinical outcomes
The following clinical outcomes will be collected to in-
form sample size calculations for the main RCT.
Development of CDC defined endometritis in the post-natal
period (days 0–30)
The development of endometritis meeting the CDC def-
inition, in the post-natal period (day 0 of delivery), is the
proposed primary outcome for the full RCT. Endometritis
will be defined as per the definitions set out by the US
Centre’s for Disease Control and Prevention (Centre’s for
Disease Control and Prevention 2017) [10].
Clinical diagnosis of endometritis in the post-natal period
(days 0–30)
Diagnosis of endometritis by a clinician which does not
meet the CDC definition or cannot be verified to meet
the definition, e.g. a woman treated in the community
for suspected endometritis where it is not feasible to es-
tablish that this meets the CDC definition or where the
diagnosis does not meet the criteria.
Maternal sepsis (days 0–42)
Defined according to the NICE sepsis guideline (released
July 2016) [10].
Length of hospital stay
The length of hospital stay from randomisation to dis-
charge home or transfer to another hospital following CS
or up to 6 weeks after randomisation if not discharged.
Readmission to hospital after CS for suspected or confirmed
infection (days 0–42)
It is defined as readmission to hospital post-discharge
home up until 6 weeks postnatally.
Antibiotic prescriptions
These are antibiotics prescribed as an inpatient and hos-
pital prescribed outpatient (days 0–42) and antibiotic
prescriptions for suspected/confirmed surgical site infec-
tion relating to the woman’s CS (uterine, pelvic, abdom-
inal wound and perineal).
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Requiring level 2 or level 3 critical care
This is defined as requiring level 2 or 3 critical care (or
obstetric HDU type care) as a result of an infection up
until 6 weeks postnatally (days 0–42).
The endometritis outcomes are collected up until day
30 to be consistent with the CDC definition of endomet-
ritis, and the sepsis related outcomes are collected up
until 6 weeks to be consistent with the national collec-
tion of post-natal sepsis.
Patient-reported outcomes
These will be determined by the qualitative component
of this feasibility study and reported as an outcome of
the feasibility study along with summary statistics pre-
specified in the statistical analysis plan.
Participant withdrawal
Informed consent is defined as the process of learning
the key facts about a clinical trial before deciding
whether or not to participate. It is a continuous and dy-
namic process, and women should be asked about their
ongoing willingness to continue participation with the
telephone interviews before the interview questions
commence. Women should be aware at the beginning
that they can freely withdraw (discontinue participation)
from the trial (or part of the trial) at any time.
Types of withdrawal as defined are as follows:
Before the intervention
The woman would like to withdraw from trial treatment,
before the intervention, is applied but is willing to be
followed up in accordance with the schedule of assess-
ments and if applicable using any central UK NHS bod-
ies for long-term outcomes (i.e. the woman has agreed
that data can be collected and used in the trial analysis).
After the intervention
The woman would like to withdraw from the trial after
the allocation is applied and does not wish to participate
in the telephone interview but is willing to be followed
up at any visits and if applicable using any central UK
NHS bodies for long-term outcomes (i.e. the woman has
agreed that data can be collected at standard visits and
used in the trial analysis, including data collected as part
of long-term outcomes).
Without follow-up
The woman would like to withdraw from the trial after
the allocation is applied and is not willing to be followed
up in any way for the purposes of the trial and for no
further data to be collected (i.e. only data collected prior
to the withdrawal can be used in the trial analysis).
Complete withdrawal
The woman wishes to withdraw completely (i.e. from
trial treatment and all follow-ups) and is not willing to
have any of their data, including that already collected,
to be used in any future trial analysis.
Adverse events and serious adverse events
The collection and reporting of adverse events (AEs) will
be in accordance with the Research Governance Frame-
work for Health and Social Care and the requirements
of the Health Research Authority (HRA). No neonatal
AEs or SAEs are required to be reported as the interven-
tion is licenced for use in obstetrics over 34 weeks for
swabbing as per the SmPC and has a demonstrated
safety record in many trials in neonates above 34 weeks
gestation [11].
Adverse events (AE)
There are certain AEs which are commonly expected in
participants as a result of pregnancy and/or CS. As these
events are well characterised, it is highly unlikely that
this trial will reveal any new safety information relating
to this intervention. Thus, there will be no AEs
recorded.
Serious adverse events (SAE)
All events which meet the definition of serious will be
collected and recorded in the participant notes and the
Case Report Form (CRF). SAEs will, in addition, be re-
ported to the trials office immediately and within 24 h of
the principal investigator being made aware of the event.
Allergic reaction to chlorohexidine requiring treatment
will be considered a serious adverse advent.
Events not considered an SAE in PREPS include:
 Hospitalisation for delivery of the baby
 The development of infection and sepsis in the
post-natal period that requires inpatient treatment
or prolongation of hospitalisation as this is an
outcome of the trial
 Obstetric haemorrhage
 Damage to bowel or bladder during surgery
 Prolonged hospitalisation due to neonatal
complications
 Thromboembolic events
All other events not detailed above that meet the def-
inition of a SAE should be reported as detailed below.
SAEs should be reported on an SAE Form. When
completing the form, the PI will be asked to define the
causality and the severity of the SAE. Causality will be
assessed as definitely related, probably related, possibly
related, unlikely to be related or unrelated. On becoming
aware that a woman has experienced an SAE, the
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Investigator or delegate(s) should report the SAE to their
own Trust in accordance with local practice and to the
BCTU trials office. On receipt of an SAE form, the Chief
Investigator (CI) or delegate(s) will independently deter-
mine the seriousness and causality of the SAE. An SAE
judged by the PI or CI or delegate(s) to have a reasonable
causal relationship with the intervention will be regarded
as a related SAE. The causality assessment given by the PI
will not be downgraded by the CI or delegate(s). If the CI
or delegate(s) disagrees with the PI’s causality assessment,
the opinion of both parties will be documented, and where
the event requires further reporting, the opinion will be
provided with the report. The CI “or delegate(s)” will also
assess all related SAEs for expectedness. If the event is un-
expected (i.e. is not defined in the protocol as an expected
event), it will be classified as an unexpected and related
SAE. BCTU will report all events categorised as unex-
pected and related SAEs to the main Research Ethics
Committee (REC) within 15 days. The main REC and
sponsor will be notified immediately if a significant safety
issue is identified during the course of the trial.
Sample size and data analysis
Sample size
Since this is a feasibility study, no formal sample size
calculations have been undertaken. The feasibility study
is not designed or powered to detect a statistically sig-
nificant difference in efficacy between the two treatment
arms. A total sample size of 250 participants would
agree with existing literature which suggests that the size
of the feasibility study should be at least 10% of the an-
ticipated size of the substantive study [12]. A recruit-
ment target of 250 participants has been chosen for this
feasibility study as we expect this number will be suffi-
cient to provide estimates of the feasibility outcomes.
Preliminary sample size calculations were computed
for the full RCT. Vaginal cleansing with povidone iodine
has been evaluated in a Cochrane review which com-
prised of seven trials randomising 2816 women (2635
analysed) estimating the effects of vaginal cleansing
(povidone-iodine) on post-caesarean infectious morbid-
ity. The risk of bias was generally low, with the quality
of most of the studies being high. Vaginal preparation
immediately before caesarean delivery significantly re-
duced the incidence of post-caesarean endometritis from
8.3% in control groups to 4.3% in vaginal cleansing
groups. To detect a difference of this size with 90%
power and alpha at 5%, we would require 1548 partici-
pants. In addition, to account for an anticipated 10% loss
to follow-up, we would need a total of 1720 participants.
Analysis of outcome measures
A separate statistical analysis plan for the PREPS feasibility
study will provide a detailed description of the planned
statistical analyses. A brief outline of the planned analyses
is given below.
All clinical outcomes will be analysed according to the
treatment arm to which they were randomised (i.e. vaginal
cleansing or no cleansing) irrespective of compliance with
the randomised treatment allocation, as per the intention
to treat principle. Women who did not undergo a CS will
be excluded from the analyses.
All feasibility outcomes will be analysed pooling the
two randomised groups and presenting overall estimates
of proportions with 95% confidence intervals, as well as
estimates by centre.
All outcomes will primarily take the form of simple
descriptive statistics (e.g. proportions and percentages,
means and standard deviations) and where appropriate,
point estimates of effect sizes (e.g. mean differences and
relative risks) and associated 95% confidence intervals.
Decision to continue to a definitive trial
The decision to continue to a full trial will be decided by
pre-defined stop-go criteria. A traffic light system has
been designed that will determine progression.
Stop-go criteria
 Recruitment rates: the proportion of women
randomised into the trial of the 250 recruitment target.
 Adherence to the allocated intervention: the
proportion of women who received their allocated
intervention out of all those randomised.
 Successful completion of follow-up: the proportion
of women remaining in the trial (i.e. not withdrawn
as per criteria below) who successfully complete the
planned follow-up process for both the 14- and 30-
day telephone interview.
 Study drop-out: withdrawal from the study.
Traffic light system
Green light: recruitment rate > 90%, adherence rate > 75%,
follow-up rate > 90% and dropout rate < 15%. If all four
criteria are met, we will proceed to a full trial with the
protocol unchanged (unless there is a clear message from
the focus groups that would improve the protocol).
Amber light: recruitment rate 80–90%, adherence rate
50–75%, follow-up rate 75–90% or dropout rate 15–30%.
If one or more of our amber light criteria are met, we will
plan to adapt the protocol in light of the feedback from
the focus groups and our experience to improve which-
ever criteria are not at the ‘green-light’ level before pro-
ceeding to full trial. We will assess whether adaption of
the protocol will require a further feasibility study or pilot
study before progressing.
Red light: recruitment rate < 80%, adherence rate < 50%,
follow-up rate < 75% or dropout rate > 30%.
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If one or more of these criteria are met, we would con-
sider the current protocol not feasible and not progress
to a full RCT.
The Trial Oversight Committee will take into consid-
eration statistical uncertainty around these rates using
95% confidence intervals.
Missing data: Every attempt will be made to collect full
follow-up data on all study participants; it is thus antici-
pated that missing data will be minimal and the strat-
egies needed to achieve this are part of this feasibility
RCT. The main analysis will use available data only;
however, the amount of missing data will be assessed,
and if necessary, sensitivity analyses will be undertaken.
Trial and data management
Sponsor
The PREPS trial is sponsored by Birmingham Women’s
and Children’s NHS Foundation Trust.
Coordinating centre
The coordinating centre is the Birmingham Clinical Tri-
als Unit at the University of Birmingham.
Trial oversight committee
Given this is a feasibility study, the Trial Oversight
Committee (TOC) will comprise of a joint trial steer-
ing committee and data monitoring committee and
will meet three times through the proposed 15-month
study. The TOC will provide supervision and advice
for the study and ensure the study is conducted as
applicable to the MRC Guidelines for Good Clinical
Practice in Clinical Trials. Trial data provided to the
TOC will be anonymised, but study group allocation
may be provided, if it is necessary for their delibera-
tions regarding serious adverse events. There is no
planned interim analysis.
Data management
Processes will be employed to facilitate the accuracy of
the data included in the final report. These processes
will be detailed in the trial specific data management
plan. Coding and validation will be agreed between the
trial’s coordinator, statistician and programmer, and the
trial database will be signed off once the implementation
of these has been assured.
Data security
The security of the trial database is governed by the pol-
icies of the University of Birmingham. The University’s
Data Protection Policy and the Conditions of Use of
Computing and Network Facilities set out the security
arrangements under which sensitive data should be
processed and stored. All studies at the University of
Birmingham have to be registered with the Data Protec-
tion Officer and data held in accordance with the Data
Protection Act. The University will designate a Data Pro-
tection Officer upon registration of the study. The study
centre has arrangements in place for the secure storage
and processing of the study data which comply with the
University of Birmingham policies.
Discussion
Post-partum infection/sepsis is a significant global prob-
lem. With the increasing evidence regarding antimicrobial
resistance and the development of bacterial resistance
there, is concern that without action, common procedures
such as CS will carry significant risks. We must, therefore,
seek strategies that reduce this risk. We aim to perform a
feasibility study for a larger multi-centre randomised
controlled trial (RCT) comparing vaginal cleansing with
chlorhexidine versus standard practice of no vaginal
cleansing immediately before CS to reduce post-partum
endometritis and sepsis. There are a number of difficulties
in performing a RCT in pregnant women undergoing CS,
particularly in an emergency procedure where there is a
short interval between decision and delivery. Additionally,
the follow-up of women post-CS is unlike other surgical
procedures: mothers are discharged from obstetric care
quickly with no routine post-operative follow-up. They
are motivated to recover and care for their baby. It is
therefore necessary to perform this feasibility trial to as-
sess both our ability to recruit women and adequately fol-
low them up. The main limitation of this feasibility study
is that it is being performed within units motivated to per-
form the feasibility trial and this may not accurately repre-
sent recruitment in all sites.
Conclusion
This is a feasibility randomised controlled trial, assessing
the feasibility of performing a trial of vaginal chlorohexidine
cleansing to prevent post-natal infection. Testing newly de-
veloped verbal consent, randomisation and follow-up pro-
cesses in this population.
Trial status
The PREPS trial opened to recruitment on 11th November
2017. At the time of submitting this protocol for publica-
tion, the trial was actively recruiting participants.
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Elective caesarean section
A suitably qualified research midwife or doctor will introduce the study to
the woman at their pre-operative assessment. A patient information leaflet
(PIL) will be provided to facilitate this process. Investigators will ensure that
they adequately explain the aim, trial treatment, anticipated benefits and
potential hazards of taking part in the trial to the woman. They will also
stress that participation is voluntary and that the woman is free to refuse
to take part and may withdraw from the trial at any time. The woman will
be given adequate time to read the PIL and to discuss their potential
participation and be given the opportunity to ask questions. If the woman
expresses an interest in participating in the trial, they will be asked to sign
and date the latest version of the Informed Consent Form. The woman will
be asked for her consent to be randomly allocated to the intervention or
standard treatment, for collection of outcome data from their medical
records and a telephone interview at 14 and 30 days postnatally that will
take approximately 5–15 min. It will be the responsibility of the investigator
to obtain written informed consent for each participant prior to performing
any trial related procedure.
A copy of the consent form will be given to the woman, a copy filed in the
medical records with the PIL. The original signed consent form will be filed
in the investigator site file.
Emergency caesarean section
In the majority of emergency CS, the woman will be asked to consent as per
the elective procedure. It is expected that the majority of women undergoing
emergency CS will provide written consent prior to trial-related procedures
commencing.
It is appreciated that time can be limited in the undertaking of an emergency
CS, especially where there is suspected maternal or foetal compromise. In
keeping with the Royal College of Obstetricians and Gynaecologist consent
advice for women participating in research, as long as information is available
antenatally, it is reasonable to take consent in labour [13]. The common
incidence of CS (an event that occurs in 25% of women) and the expectation
of women in labour that CS is a possibility means that giving information to all
women would not overburden them and is unlikely to cause anxiety or deviate
women from the normal birth process. In the emergency situation where time
is limited, verbal consent for the intervention will be obtained prior to
randomisation with written consent to continue with the trial taken following
the CS procedure and before discharge.
In an emergency, where verbal consent is being taken, a suitably qualified
research midwife or doctor will discuss the study to the women. A verbal
discussion will include confirmation that the woman has previously received
information regarding the trial, understands that the choice of intervention
will be made randomly and is willing to take part.
After the procedure, a PIL will be provided highlighting the follow-up and
confirmation of willingness to continue to participate. They will also stress
that participation is voluntary and that she is free to refuse to take part and
may withdraw from the trial at any time. If the woman is willing to continue
to participate in the trial, she will be asked to sign and date the latest version
of the ICF.
Ancillary and post-trial care
Participants can be referred to the Patient Advisory Liaison Service if required.
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